Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thyroid carcinoma.

Steven I Sherman1

  • 1Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Texas, Houston 77030, USA. sisherma@mdanderson.org

Lancet (London, England)
|February 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Reported Symptom Burden Among Thyroid Cancer Survivors: Retrospective Cohort Study.

JCO clinical cancer informatics·2026
Same author

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Frontiers in oncology·2026
Same author

Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma.

JCO precision oncology·2026
Same author

Increasing Access and Quality Care for Immune Checkpoint Inhibitor-Related Thyroid Dysfunction.

JCO oncology practice·2025
Same author

Activating <i>RET</i> Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer.

bioRxiv : the preprint server for biology·2025
Same author

Erratum: NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy.

JCO precision oncology·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Thyroid carcinoma treatment involves surgery and radioiodine, with thyroid hormone suppression aiding recurrence prevention. Novel therapies are needed for advanced thyroid cancer, and genetic testing aids inherited syndromes.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Thyroid carcinomas are rare, varying from indolent papillary to lethal anaplastic types.
  • Established guidelines exist for diagnosis and initial management, often recommending multimodality treatments.
  • Evidence from prospective trials supporting multimodality approaches is limited.

Purpose of the Study:

  • To summarize current understanding and management of thyroid carcinomas.
  • To highlight the need for improved treatments for advanced and high-risk thyroid cancers.
  • To emphasize the role of genetic testing in inherited thyroid cancer syndromes.

Main Methods:

  • Review of current treatment strategies for thyroid carcinoma.
  • Discussion of surgical resection, radioiodine therapy, and thyroid hormone suppression.

Related Experiment Videos

  • Consideration of genetic testing for inherited thyroid cancer syndromes.

    • Main Results:

    • Surgical resection is the primary treatment for local control.
    • Adjuvant radioiodine therapy is common for papillary and follicular types.
    • Thyroid hormone suppression may prevent recurrence in specific thyroid cancer types.
    • Limited benefit exists for progressive metastatic disease, necessitating new therapeutic strategies.

    Conclusions:

    • Multidisciplinary care and patient education are crucial for informed decision-making.
    • Early diagnosis and intervention, particularly in inherited syndromes, can improve outcomes.
    • There is a significant need for novel treatment approaches for aggressive and metastatic thyroid carcinomas.